Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Mulder, FI; Candeloro, M; Kamphuisen, PW; Di Nisio, M; Bossuyt, PM; Guman, N; Smit, K; Buller, HR; van Es, N; Abdel-Razeq, H; Ades, S; Ayappan, SR; Borchmann, S; Cella, CA; Fankhauser, CD; Ferroni, P; Fuentes, HE; Kruger, S; Lim, SH; Lubberts, S; Lustig, DB; Mansfield, AS; Martin, AJM; Noble, S; Panizo, E; Papaxoinis, G; Park, K; Patel, JN; Posch, F; Ramos, JD; Roselli, M; Santi, R; Sohal, D; Srikanthan, A; Tafur, AJ; Terbuch, A; Thomas, M; Vathiotis, O; Wang, R; Zahir, MN; CAT-prediction Collaborators.

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

HAEMATOLOGICA. 2019; 104(6): 1277-1287 Nº de citas: 233 [doi:10.3324/haematol.2018.209114]

Perez, EA; de Haas, SL; Eiermann, W; Barrios, CH; Toi, M; Im, YH; Conte, PF; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Stanzel, S; Patre, M; Ellis, PA.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC CANCER. 2019; 19: Nº de citas: 51 [doi:10.1186/s12885-019-5687-0]

Perez-Ruiz, E; Minute, L; Otano, I; Alvarez, M; Ochoa, MC; Belsue, V; de Andrea, C; Rodriguez-Ruiz, ME; Perez-Gracia, JL; Marquez-Rodas, I; Llacer, C; Alvarez, M; de Luque, V; Molina, C; Teijeira, A; Berraondo, P; Melero, I.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

NATURE. 2019; 569(7756): 428 Nº de citas: 371 [doi:10.1038/s41586-019-1162-y]

Moreno, F; Gayarre, J; Lopez-Tarruella, S; del Monte-Millan, M; Picornell, AC; Alvarez, E; Garcia-Saenz, JA; Jerez, Y; Marquez-Rodas, I; Echavarria, I; Palomero, M; Bueno, C; Bodi, AMA; Munoz, MS; del Val, RG; Bueno, O; Cebollero-Presmanes, M; Ocana, I; Arias, A; Romero, P; Massarrah, T; Ramos-Medina, R; Martin, M.

Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study

Jco Precision Oncology. 2019; 3: Nº de citas: 13 [doi:10.1200/PO.18.00263]

Trilla-Fuertes, L; Gamez-Pozo, A; Prado-Vazquez, G; Zapater-Moros, A; Diaz-Almiron, M; Fortes, C; Ferrer-Gomez, M; Lopez-Vacas, R; Blanco, VP; Marquez-Rodas, I; Soria, A; Vara, JAF; Espinosa, E.

Melanoma proteomics suggests functional differences related to mutational status

Scientific Reports. 2019; 9: Nº de citas: 11 [doi:10.1038/s41598-019-43512-z]

Garcia-Alfonso, P; Torres, G; Garcia, G; Gallego, I; Ortega, L; Sandoval, C; Munoz, A; Lloansi, A.

FOLFOXIRI plus biologics in advanced colorectal cancer

EXPERT OPINION ON BIOLOGICAL THERAPY. 2019; 19(5): 411-422 Nº de citas: 7 [doi:10.1080/14712598.2019.1595580]

Aznar, MA; Planelles, L; Perez-Olivares, M; Molina, C; Garasa, S; Etxeberria, I; Perez, G; Rodriguez, I; Bolanos, E; Lopez-Casas, P; Rodriguez-Ruiz, ME; Perez-Gracia, JL; Marquez-Rodas, I; Teijeira, A; Quintero, M; Melero, I.

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

Journal for ImmunoTherapy of Cancer. 2019; 7: Nº de citas: 115 [doi:10.1186/s40425-019-0568-2]

Santos, C; Azuara, D; Vieitez, JM; Paez, D; Falco, E; Elez, E; Lopez-Lopez, C; Valladares, M; Robles-Diaz, L; Garcia-Alfonso, P; Buges, C; Duran, G; Salud, A; Navarro, V; Capella, G; Aranda, E; Salazar, R; de Mena, IR; Rodriguez, S.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

ANNALS OF ONCOLOGY. 2019; 30(5): 796-803 Nº de citas: 17 [doi:10.1093/annonc/mdz082]

Macarulla, T; Carrato, A; Diaz, R; Garcia, A; Laquente, B; Sastre, J; Alvarez, R; Munoz, A; Hidalgo, M.

Management and supportive treatment of frail patients with metastatic pancreatic cancer

Journal of Geriatric Oncology. 2019; 10(3): 398-404 Nº de citas: 6 [doi:10.1016/j.jgo.2018.06.005]

Colomer, R; Saura, C; Sanchez-Rovira, P; Pascual, T; Rubio, IT; Burgues, O; Marcos, L; Rodriguez, CA; Martin, M; Lluch, A.

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

ONCOLOGIST. 2019; 24(5): 603-611 Nº de citas: 51 [doi:10.1634/theoncologist.2018-0228]

Camp, NJ; Madsen, MJ; Herranz, J; Rodriguez-Lescure, A; Ruiz, A; Martin, M; Bernard, PS.

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2019; 175(1): 129-139 Nº de citas: 10 [doi:10.1007/s10549-018-05097-5]

Pascual, T; Martin, M; Fernandez-Martinez, A; Pare, L; Alba, E; Rodriguez-Lescure, A; Perrone, G; Cortes, J; Morales, S; Lluch, A; Urruticoechea, A; Gonzalez-Farre, B; Galvan, P; Jares, P; Rodriguez, A; Chic, N; Righi, D; Cejalvo, JM; Tonini, G; Adamo, B; Vidal, M; Villagrasa, P; Munoz, M; Prat, A.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

Frontiers in Oncology. 2019; 9: Nº de citas: 9 [doi:10.3389/fonc.2019.00303]

Lebbe, C; Meyer, N; Mortier, L; Marquez-Rodas, I; Robert, C; Rutkowski, P; Menzies, AM; Eigentler, T; Ascierto, PA; Smylie, M; Schadendorf, D; Ajaz, M; Svane, IM; Gonzalez, R; Rollin, L; Lord-Bessen, J; Saci, A; Grigoryeva, E; Pigozzo, J.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(11): 867 Nº de citas: 293 [doi:10.1200/JCO.18.01998]

Delaloge, S; Cella, D; Ye, Y; Buyse, M; Chan, A; Barrios, CH; Holmes, FA; Mansi, J; Iwata, H; Ejlertsen, B; Moy, B; Chia, SKL; Gnant, M; Smichkoska, S; Ciceniene, A; Martinez, N; Filipovic, S; Ben-Baruch, NE; Joy, AA; Langkjer, ST; Senecal, F; de Boer, RH; Moran, S; Yao, B; Bryce, R; Auerbach, A; Fallowfield, L; Martin, M.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

ANNALS OF ONCOLOGY. 2019; 30(4): 567-574 Nº de citas: 19 [doi:10.1093/annonc/mdz016]

Mendez, M; Torrente, M; Sanchez-Beato, M; Gonzalez-Rincon, J; Royuela, A; Gomez-Codina, J; de la Cruz-Merino, L; Rueda, A; Llanos, M; Quero, C; Rodriguez-Abreu, D; Guma, J; Monsalvo, S; Sabin, P; Provencio, M.

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

HEMATOLOGICAL ONCOLOGY. 2019; 37(2): 143-150 Nº de citas: 11 [doi:10.1002/hon.2601]

Chia, SKL; Martin, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H; von Minckwitz, G; Mansi, J; Barrios, CH; Gnant, M; Tomasevic, Z; Denduluri, N; Separovic, R; Kim, SB; Jakobsen, EH; Harvey, V; Robert, N; Smith, J; Harker, G; Zhang, B; Eli, LD; Ye, YN; Lalani, AS; Buyse, M; Chan, A.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

BREAST CANCER RESEARCH. 2019; 21: Nº de citas: 16 [doi:10.1186/s13058-019-1115-2]

Lope, V; Martin, M; Castello, A; Ruiz, A; Casas, AM; Baena-Canada, JM; Antolin, S; Ramos-Vazquez, M; Garcia-Saenz, JA; Munoz, M; Lluch, A; de Juan-Ferre, A; Jara, C; Sanchez-Rovira, P; Anton, A; Chacon, JI; Arcusa, A; Jimeno, MA; Bezares, S; Vioque, J; Carrasco, E; Perez-Gomez, B; Pollan, M.

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

Scientific Reports. 2019; 9: Nº de citas: 26 [doi:10.1038/s41598-019-39346-4]

Vidal, J; Bellosillo, B; Vivas, CS; Garcia-Alfonso, P; Carrato, A; Cano, MT; Garcia-Carbonero, R; Elez, E; Losa, F; Massuti, B; Valladares-Ayerbes, M; Vieitez, JM; Manzano, JL; Azuara, D; Gallego, J; Pairet, S; Capella, G; Salazar, R; Tabernero, J; Aranda, E; Montagut, C.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

ANNALS OF ONCOLOGY. 2019; 30(3): 439-446 Nº de citas: 15 [doi:10.1093/annonc/mdz005]